Actinium Pharmaceuticals, Inc, also called Actinium Pharmaceuticals, is a clinical-stage biopharmaceutical company. It is focused on developing Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Read More The firm provides its service through Iomab-B, which is studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The company was founded in 2002 and is headquartered in New York, NY. The listed name for ATNM is Actinium Pharmaceuticals, Inc.